Credit Suisse Group set a $288.00 price target on Allergan PLC. (NYSE:AGN) in a report published on Saturday. The firm currently has a buy rating on the stock.

AGN has been the topic of several other reports. UBS AG restated a buy rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Vetr upgraded Allergan PLC. from a sell rating to a hold rating and set a $242.88 price objective on the stock in a report on Monday, June 26th. Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the stock a buy rating in a report on Monday, June 12th. BidaskClub upgraded Allergan PLC. from a hold rating to a buy rating in a report on Saturday, June 24th. Finally, Mizuho restated a buy rating and set a $267.00 price objective on shares of Allergan PLC. in a report on Wednesday, August 2nd. Seven research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Allergan PLC. has an average rating of Buy and an average price target of $274.14.

Shares of Allergan PLC. (NYSE:AGN) opened at 241.22 on Friday. The company has a market capitalization of $81.02 billion, a price-to-earnings ratio of 7.52 and a beta of 1.16. The company’s 50 day moving average price is $245.21 and its 200 day moving average price is $237.12. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the business posted $3.35 EPS. On average, analysts predict that Allergan PLC. will post $16.20 EPS for the current year.

WARNING: “Credit Suisse Group Analysts Give Allergan PLC. (NYSE:AGN) a $288.00 Price Target” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/08/credit-suisse-group-analysts-give-allergan-plc-nyseagn-a-288-00-price-target.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.16%. Allergan PLC.’s payout ratio is 9.95%.

In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of AGN. Veritas Asset Management LLP purchased a new stake in shares of Allergan PLC. during the first quarter worth approximately $761,339,000. Edgewood Management LLC boosted its stake in shares of Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after buying an additional 178,055 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after buying an additional 73,081 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock worth $476,713,000 after buying an additional 5,042 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. boosted its stake in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after buying an additional 370,400 shares in the last quarter. 84.77% of the stock is owned by hedge funds and other institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.